melanotan-ii

skin tanning without sun. also triggers sexual arousal. both off-label. both widely used.

tier A · skin · RUO not approved

verdict

tanning without sun. also appetite suppression and sexual arousal. all off-label, all reproducible, and the melanoma case-report literature is real.

if you're asking whether MT-II actually tans skin — yes. MC1R activation drives eumelanin synthesis. effects are dose-dependent, reproducible, and not subtle. a tan within days at moderate doses. it is cheap on the gray market. the same MC4R activation that suppresses appetite and increases sexual arousal is also what spawned PT-141. UK tabloids called it the barbie drug; social media did the rest.

if you're asking about melanoma risk — the case-report literature is real. multiple published cutaneous melanomas in MT-II users (5+ documented), plus a 2025 anterior-maxilla mucosal melanoma after MT-II nasal-spray use (Int J Oral Maxillofac Surg, PMID 40210573) that implicates the nasal route specifically. most cases are attributed to sun-seeking behavior (users combining MT-II with tanning beds) rather than direct carcinogenesis, which actively undermines the original cancer-prevention hypothesis MT-II was invented for. FDA, MHRA, TGA, and multiple European regulators have all issued warnings.

if you're asking about the broader side-effect profile — mole changes, priapism, hyperpigmentation. these are exactly what the MC1R/MC4R/MC5R map predicts and they're reported consistently. gray-market product purity is genuinely variable. same molecule on a structure drawing, different concentrations and identity controls across vendors. the receptor pharmacology does what it says; the supply chain is the variable nobody controls for.

based on published evidence and disclosed clinical practice. not medical advice.

why A-tier

originally developed by University of Arizona researchers in the 1980s-90s as a potential skin cancer chemoprevention agent. The hypothesis was that stimulating endogenous melanin production could create protective pigmentation without UV exposure. no FDA-approved melanotan II product exists. commercial development was abandoned by Palatin in 2000 after the arousal-active metabolite (PT-141) appeared more promising. lives on entirely as a gray-market tanning compound. FDA, UK MHRA, Australian TGA, and multiple other regulatory bodies have issued warnings. A-tier based on mechanism validity and consistent user reports, with heavy caveats about melanoma case reports and gray-market product quality.

the core tension

Developed to prevent skin cancer. Now sold on Instagram as a tanning drug. The paradox is that real-world users combine it with tanning beds, which is exactly what the compound was invented to make unnecessary.

what it is

a synthetic cyclic heptapeptide and non-selective agonist at MC1R through MC5R. shortened, cyclized analog of alpha-MSH, longer-lived than the native hormone. no FDA-approved melanotan II drug product exists for any indication. the related, distinct compound melanotan I (afamelanotide, Scenesse) is FDA-approved for erythropoietic protoporphyria, which fuels persistent confusion.

what it does

MC1R activation drives eumelanin synthesis, that is the tan. MC4R activation suppresses appetite and pushes sexual arousal. MC5R hits sebaceous glands. effects are real, dose-dependent, and not particularly subtle. the same MC4R activation is what spawned PT-141.

origin

Mac Hadley and Victor Hruby at the University of Arizona in the 1980s and 1990s, with the explicit goal of pharmacological skin cancer chemoprevention. Palatin abandoned the program in 2000 in favor of PT-141. Clinuvel licensed it in 2006, ran into regulatory resistance, and refocused on melanotan I. melanotan II itself never reached approval anywhere.

why researchers are interested

the tanning effect is reproducible and pronounced, a tan within days at moderate doses, plus appetite suppression and arousal as bundled side effects users either tolerate or actively want. cheap on the gray market. UK tabloids called it the barbie drug. social media did the rest.

does it work

for tanning, yes, mechanistically and reliably. for what it was actually invented to do, prevent skin cancer, the real-world use pattern actively undermines the original hypothesis: users frequently combine MT-II with tanning beds. multiple published melanoma case reports exist, including 5+ documented cutaneous cases and a 2025 anterior-maxilla mucosal melanoma after MT-II nasal-spray use (Int J Oral Maxillofac Surg, PMID 40210573) that implicates the nasal route specifically. Most cases are attributed to sun-seeking behavior rather than direct carcinogenesis. FDA, MHRA, TGA, and multiple European regulators have all issued warnings. gray-market product purity is genuinely variable. it does what it says, and the side effects, mole changes, priapism, hyperpigmentation, are exactly what the receptor map predicts.

claims vs the data

• causes skin tanning without sun exposure — supported — mechanism is direct, MC1R activation on melanocytes triggers eumelanin synthesis. effect is real and dose-dependent.
• protects against skin cancer — contradicted — this was the original research hypothesis. observational data suggests Melanotan users exhibit MORE sun-seeking behavior, likely increasing UV exposure and cancer risk.
• has been linked to melanoma — partially true — multiple case reports of melanomas during/after use (≥5 documented). 2021 review concluded increased risk probably explained by sun-seeking behavior, not direct carcinogenesis. 2013 review found no conclusive causal evidence.
• causes appetite suppression and weight loss — supported — MC4R activation in hypothalamus suppresses appetite. effect is real but inconsistent; sometimes described as welcome side effect by users, sometimes as uncomfortable nausea.
• causes sexual arousal — supported — MC4R activation in limbic circuits drives arousal. this is the effect that led to the spin-off drug PT-141/Vyleesi.
• nasal spray versions work as well as injection — weak — bioavailability of intranasal melanotan is poor and inconsistent. most effect reports come from subcutaneous injection.
• safe for long-term use — unverified — no long-term controlled human studies. case reports of eruptive nevi, atypical nevi, and new moles. regulatory agencies advise against use.
• melanotan II is a safer cosmetic tan — overreach — The tanning and erectogenic biology are real, but the safety story is not clean: nausea, yawning, spontaneous erections, pigmentation changes, pigmented-lesion case reports, and unregulated sourcing all matter. Cosmetic framing understates the risk package.

key facts

• molecular formula: C₅₀H₆₉N₁₅O₉
• molecular weight: 1024.2 g/mol
• amino acids: 7 (cyclic heptapeptide)
• half-life: ~30-60 minutes
• type: non-selective melanocortin receptor agonist
• CAS: 121062-08-6
• 1980s university of arizona origin
• 2000 palatin abandons development
• 0 FDA approvals anywhere
• barbie drug UK tabloid nickname

frequently asked questions

What is Melanotan II?

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH). Developed at the University of Arizona in the 1980s, it's a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R.

What does Melanotan II do?

MT-II stimulates melanin production (tanning) via MC1R activation, and produces sexual effects (libido, erectile function) via MC4R activation. Community reports describe reliable tanning over weeks and notable sexual effects.

How is Melanotan II typically administered?

There is no FDA-approved administration protocol, no approved product, and no medically supervised label context for melanotan II. Community discussion exists but is not a use guide.

What are the side effects of Melanotan II?

Notable side effects include significant nausea (especially initial doses), spontaneous erections, facial flushing, darkening and growth of existing moles and freckles, occasional new nevus formation, appetite suppression, and skin pigmentation that may become uneven. Side effect profile is more pronounced than Melanotan I.

Is Melanotan II FDA approved?

No. MT-II is not FDA-approved for any indication and is classified as a research chemical. The Australian TGA and other international regulators have issued public warnings against grey-market cosmetic use. The related compound PT-141 (bremelanotide) was developed from MT-II and is FDA-approved for sexual dysfunction.

How much does Melanotan II cost?

No clinical retail price exists. On the research-chemical market it is one of the lower-priced peptides, reflecting its small molecular size and synthesis simplicity.

related peptides

• pt-141 — spin-off, arousal metabolite, FDA-approved as Vyleesi

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.